A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals

Simply Wall St.05-11

Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634750024?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-11 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634750024","market":"us","top_or_hot":-1,"title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals","media":"Simply Wall St.","content":"<div>\n<p>Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-11 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd-1","article_id":"2634750024","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-rezd-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634750024","pubTimestamp":1778465576,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused licensing deals and pipeline additions.\nSee our latest analysis for Madrigal Pharmaceuticals.\nThe share price has been volatile, with a 30 day share price return of 4.49% and a 90 day share price return of 11.99%. Yet year to date it is down 9.94%, while the 1 year total shareholder return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MDGL":"Madrigal Pharmaceuticals, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Rezdiffra重磅里程碑和新的MASH管道交易后Madrigal Pharmaceuticals(MDGL)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1.5},"content_text":"Madrigal Pharmaceuticals (MDGL) drew fresh attention after reporting Q1 2026 results, with Rezdiffra reaching blockbuster territory and more than 42,000 patients on therapy, alongside new MASH focused licensing deals and pipeline additions. See our latest analysis for Madrigal Pharmaceuticals. The share price has been volatile, with a 30 day share price return of 4.49% and a 90 day share price return of 11.99%. Yet year to date it is down 9.94%, while the 1 year total shareholder return of 78.54% and 5 year total shareholder return above 3x the starting level point to momentum built over a longer horizon as investors respond to blockbuster Rezdiffra sales, recent Q1 results and ongoing pipeline expansion. If the recent move in Madrigal has you thinking about what else is gaining attention in healthcare, it could be worth scanning 35 healthcare AI stocks as a starting list of ideas. With Rezdiffra already a blockbuster, a strong revenue run rate and Wall Street targets sitting above the current US$534.86 share price, investors now face a key question: is Madrigal undervalued or is future growth already priced in? AdvertisementMost Popular Narrative: 20.3% Undervalued Against the last close of $534.86, the most followed narrative pegs fair value at $671.07, framing Madrigal as undervalued on a discounted cash flow view using a 7.08% discount rate.  The analyst price target for Madrigal Pharmaceuticals has been revised higher to $671.07, up from $603.47. Analysts now factor in updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E, following recent research that highlights both enthusiasm for Rezdiffra's commercial potential and some valuation concerns.  Read the complete narrative. Want to see what is driving that higher fair value line? The narrative leans on ambitious revenue expansion, margin uplift and a richer future earnings multiple. Curious which specific forecasts and valuation levers have to hold for this pricing to make sense? The full story spells out the assumptions in detail. Result: Fair Value of $671.07 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside story can crack if Rezdiffra underperforms in later stage MASH or if GLP 1 competitors and reimbursement pressure tighten pricing and margins. Find out about the key risks to this Madrigal Pharmaceuticals narrative. Next Steps With sentiment split between strong rewards and clear risks, it makes sense to move quickly and check the full risk reward balance for yourself by reviewing the 3 key rewards and 1 important warning sign. Looking for more investment ideas? If you stop with just one stock, you could miss other compelling setups that fit your style. Take a few minutes to widen your watchlist using focused screeners.  Target potential mispricings by scanning companies flagged as 51 high quality undervalued stocks where quality and price might be pulling in different directions. Prioritise resilience by reviewing 71 resilient stocks with low risk scores that may offer steadier profiles when you want less drama in your portfolio. Get ahead of the crowd by checking a screener containing 23 high quality undiscovered gems before they attract wider market attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634750024","isCrawlerRequest":true}